Cleveland BioLabs - Best Pharma Stocks of 2007

Company: Cleveland BioLabs
Starting stock price: $4.78
Ending stock price: $8.80
Percent Change: 84.10%

Details: Cleveland BioLabs is a spin-off of the famed Cleveland Clinic. The company is developing drugs using its mechanistic discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. Cleveland BioLabs is conduction clinical trials of Curaxin CBLC102 prostate cancer, CBLC102 for renal cell carcinoma, and CBLB502 for acute radiation syndrome.

More News:
Cleveland Clinic spinoff goes public. Report

Cleveland BioLabs - Best Pharma Stocks of 2007

Suggested Articles

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.

Several of GlaxoSmithKline's vaccines are riding strong momentum and now the drugmaker is selling two assets to focus on those growth products.